Research Article
The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
Table 1
Characteristics of the included trials.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NSCLC: nonsmall cell lung cancer; RCC: renal cell carcinoma; TNBC: triple-negative breast cancer; NR: not reached; IHC: immunohistochemistry; Type 1 = membranous staining on tumor cells; Type 2 = membranous or cytoplasmic staining, or both, of tumor cells and tumor-infiltrating immune cells; all the included patients in KEYNOTE-024 were patients with PD-L1 ≥50%; the experimental arm of KEYNOTE-010 comprised two cohorts: pembrolizumab 2 mg/kg () and pembrolizumab 10 mg/kg (), and all the included patients in KEYNOTE-010 were patients with PD-L1 ≥1%; the experimental arm of KEYNOTE-006 comprised two cohorts: intravenous pembrolizumab every 2 weeks () and intravenous pembrolizumab every 3 weeks (); here, we combined these two cohorts as the experimental arm to compare with ipilimumab group (control arm; ); the experimental arm of CheckMate 067 comprised two cohorts: nivolumab-plus-ipilimumab group () and nivolumab group (); these two cohorts were compared with ipilimumab group (), respectively; the IMpower150 had three cohorts: BCP cohort (bevacizumab plus carboplatin plus paclitaxel), ACP cohort (atezolizumab plus carboplatin plus paclitaxel), and ABCP cohort (atezolizumab plus BCP); here, the ABCP cohort was compared with the BCP cohort before the ACP cohort was compared with the BCP cohort. |